Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

Journal of Clinical Investigation

Volumn 109, Issue 3, 2002, Pages 409-417

  Heiser, Axel ^a   Coleman, Doris ^a   Dannull, Jens ^a   Yancey, Donna ^a   Maurice, Margaret A ^a   Lallas, Costas D ^a   Dahm, Philipp ^a   Niedzwiecki, Donna ^b   Gilboa, Eli ^a,c   Vieweg, Johannes ^a,c  

^a Division of Urology   (United States)

^b Department of Biostatistics ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TUMOR VACCINE;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

EID: 0036167308     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0214364     Document Type: Article

References (25)

1. Prostate cancer, incidence, management and outcomes
2. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
3. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells
4. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
5. Dendritic cells and the control of immunity
6. Immunotherapy of cancer with dendritic-cell-based vaccines
7. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
8. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
9. Induction of primary CEA-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
10. Human dendritic cells transfected with RNA encoding PSA stimulate prostate specific CTL responses in vitro
11. Calculation of lyric units for the expression of cell-mediated cytotoxicity
12. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
13. Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man
14. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
15. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
16. The biology of the 17-1A antigen (Ep-CAM)
17. Human dendritic cells pulsed with renal tumor RNA stimulate tumor specific CTL in vitro without inducing autoimmune toxicity
18. Induction of polyclonal prostate cancer specific cytotoxic T lymphocytes using dendritic cells transfected with amplified tumor RNA
19. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
20. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
21. Phase I clinical trial: T-cell therapy for prostate cancer using dendritic cells pulsed with HLA-201-specific peptides from prostate-specific membrane antigen
22. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
23. Antigen-specific inhibition of effecror T cell function in humans after injection of immature dendritic cells
24. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response
25. Micrometastatic bone marrow involvement: Detection and prognostic significance